Depatuxizumab Mafodotin Uses, Dosage, Side Effects and more
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Selectively targets cancer cells expressing mutant epidermal growth factor receptor (EGFR) vIII or over expressing wild type EGFR . Depatuxizumab Mafodotin acts on these cells to inhibit microtuble polymerization thus disrupting mitosis and vesicular trafficking
| Attribute | Details |
|---|---|
| Trade Name | Depatuxizumab Mafodotin |
| Generic | Depatuxizumab mafodotin |
| Depatuxizumab mafodotin Other Names | Denintuzumab mafodotin, Depatuxizumab mafodotin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
No approved indication.
How Depatuxizumab Mafodotin works
Depatuxizumab is a chimeric monoclonal antibody for EGFR which is linked to monomethyl aurastatin F via a maleimidocaproyl linker (mafodotin) . Once delivered to the cancer cell, the mafodotin component is able to bind to tubulin and inhibit the exchange of GDP for GTP necessary for the polymerization of tubulin subunits to form microtubules. The inhibition of microtubule polymerization disrupts mitosis and interferes with vesicle trafficking in the cancer cell .
